PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Clinical Results Presented from Prothena's Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease
All dose levels of PRX002/RG7935 found to have an acceptable safety and tolerability profile, meeting the primary objective of this study Robust central nervous system (CNS) penetration demonstrated by a dose-dependent increase in PRX002 levels in cerebrospinal fluid (CSF), and mean concentration
View HTML
Toggle Summary Data for Prothena's NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting
DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2
View HTML
Toggle Summary Data From Prothena's Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology
Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association
View HTML
Toggle Summary Data from Prothena's Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid
Antibodies bind specifically to misfolded, non-native forms of transthyretin, disrupting fibril formation
View HTML
Toggle Summary Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion,
View HTML
Toggle Summary Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences
DUBLIN, Ireland, April 23, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dale Schenk, PhD, the Company's President
View HTML
Toggle Summary Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders
Elan Announces Plan to Spin-Off Discovery Science And Neotope Biosciences to Shareholders Creates two independent, unique companies Transaction aligns assets, timelines, and risk/reward Elan to become immediately profitable and a high growth company Targeting $1.00 earnings per share by 2015 with
View HTML
Toggle Summary First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's Disease
Entering clinic triggers $15 million milestone payment from Roche DUBLIN, Ireland, April 8, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential
View HTML
Toggle Summary First Patient Dosed in Phase I Study of Prothena's Therapeutic Antibody for Treatment of AL Amyloidosis
NEOD001 Enters Clinic With Orphan Designation and Potential to Meet Significant Unmet Need
View HTML
Toggle Summary First-In-Human Assessment of PRX002, Prothena's Anti-Alpha Synuclein Antibody for Parkinson's Disease, Published in Movement Disorders Journal
Data Previously Presented in 2015 at 19th International Congress of Parkinson's Disease and Movement Disorders
View HTML